Chemical cross-linking of HIV-1 Env for direct TLR7/8 ligand conjugation compromises recognition of conserved antigenic determinants

Virology

Volumn 446, Issue 1-2, 2013, Pages 56-65

  Feng, Yu ^a,b   Forsell, Mattias N E ^a,c   Flynn, Barbara ^a   Adams, William ^c   Loré, Karin ^c   Seder, Robert ^a   Wyatt, Richard T ^a,b   Karlsson Hedestam, Gunilla B ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cross linker; HIV 1 envelope glycoprotein; Neutralizing antibody; Toll like receptor ligand

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 120; GP 120 TOLL LIKE RECEPTOR 7 CONJUGATE; GP 120 TOLL LIKE RECEPTOR 8 CONJUGATE; IMMUNOMODULATING AGENT; LYSINE; MALEIMIDE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBODY COMBINING SITE; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGENICITY; ARTICLE; BINDING KINETICS; CELL STIMULATION; CONTROLLED STUDY; CROSS LINKING; DENDRITIC CELL; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; LIGAND BINDING; MOLECULAR RECOGNITION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

CROSS-LINKER; HIV-1 ENVELOPE GLYCOPROTEIN; NEUTRALIZING ANTIBODY; TOLL-LIKE RECEPTOR LIGAND;

ANTIGENS, CD4; EPITOPES; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; PROTEIN BINDING; TOLL-LIKE RECEPTOR 7;

EID: 84884504276     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.07.028     Document Type: Article

References (41)

1. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2(8):675-680.
2. Baldwin S.L., Bertholet S., Reese V.A., Ching L.K., Reed S.G., Coler R.N. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 2012, 188(5):2189-2197.
3. Bekeredjian-Ding I.B., Wagner M., Hornung V., Giese T., Schnurr M., Endres S., Hartmann G. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 2005, 174(7):4043-4050.
4. Blander J.M., Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006, 440(7085):808-812.
5. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32(3):305-315.
6. Bourke E., D Bosisio, J Golay, N Polentarutti, A Mantovani The Toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood 2003, 102:956-963.
7. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 2004, 5(3):233-236.
8. Carter D., Reed S.G. Role of adjuvants in modeling the immune response. Curr. Opin. HIV AIDS 2010, 5(5):409-413.
9. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33(4):492-503.
10. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Adhami M.A., Krieg A.M., Cameron D.W., Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J. Clin. Immunol. 2004, 24(6):693-701.
11. Cooper C.L., Davis H.L., Morris M.L., Efler S.M., Krieg A.M., Li Y., Laframboise C., Al Adhami M.J., Khaliq Y., Seguin I., Cameron D.W. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004, 22(23-24):3136-3143.
12. Crompton P.D., Mircetic M., Weiss G., Baughman A., Huang C.Y., Topham D.J., Treanor J.J., Sanz I., Lee F.E., Durbin A.P., Miura K., Narum D.L., Ellis R.D., Malkin E., Mullen G.E., Miller L.H., Martin L.B., Pierce S.K. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J. Immunol. 2009, 182(5):3318-3326.
13. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., Hoff S.T., Andersen P., Reed S.G., Morris S.L., Roederer M., Seder R.A. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 2007, 13(7):843-850.
14. Douagi I., Gujer C., Sundling C., Adams W.C., Smed-Sorensen A., Seder R.A., Karlsson Hedestam G.B., Lore K. Human B cell responses to TLR ligands are differentially modulated by myeloid and plasmacytoid dendritic cells. J. Immunol. 2009, 182(4):1991-2001.
15. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 2007, 5(7):505-517.
16. Henao-Mejia J., Elinav E., Strowig T., Flavell R.A. Inflammasomes: far beyond inflammation. Nat. Immunol. 2012, 13(4):321-324.
17. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., Song L., Nakaar V., Powell T.J. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25(4):763-775.
18. Jackson D.C., Lau Y.F., Le T., Suhrbier A., Deliyannis G., Cheers C., Smith C., Zeng W., Brown L.E. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc. Nat. Acad. Sci. U.S.A. 2004, 101(43):15440-15445.
19. Jacobs S.R., Damania B. NLRs, inflammasomes, and viral infection. J. Leukoc. Biol. 2012.
20. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 2008, 6(2):143-155.
21. Kastenmuller K., Wille-Reece U., Lindsay R.W., Trager L.R., Darrah P.A., Flynn B.J., Becker M.R., Udey M.C., Clausen B.E., Igyarto B.Z., Kaplan D.H., Kastenmuller W., Germain R.N., Seder R.A. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 2011, 121(5):1782-1796.
22. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11(5):373-384.
23. Lanzavecchia A., Sallusto F. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr. Opin. Immunol. 2007, 19(3):268-274.
24. Loo Y.M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34(5):680-692.
25. Lore K., Betts M.R., Brenchley J.M., Kuruppu J., Khojasteh S., Perfetto S., Roederer M., Seder R.A., Koup R.A. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J. Immunol. 2003, 171(8):4320-4328.
26. Lore K., Karlsson Hedestam G.B. Novel adjuvants for B cell immune responses. Curr. Opin. HIV AIDS 2009, 4(5):441-446.
27. Lousada-Dietrich S., Jogdand P.S., Jepsen S., Pinto V.V., Ditlev S.B., Christiansen M., Larsen S.O., Fox C.B., Raman V.S., Howard R.F., Vedvick T.S., Ireton G., Carter D., Reed S.G., Theisen M. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate. Vaccine 2011, 29(17):3284-3292.
28. Mascola J.R., Montefiori D.C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28:413-444.
29. Mullen G.E., Giersing B.K., Ajose-Popoola O., Davis H.L., Kothe C., Zhou H., Aebig J., Dobrescu G., Saul A., Long C.A. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006, 24(14):2497-2505.
30. Oh J.Z., Kedl R.M. The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity. J. Immunol. 2010, 185(8):4602-4608.
31. Pattacini L., Mize G.J., Graham J.B., Fluharty T.R., Graham T.M., Lingnau K., Wizel B., Perdiguero B., Esteban M., Pantaleo G., Shen M., Spies G.A., McElrath M.J., Lund J.M. A Novel HIV Vaccine Adjuvanted by IC31 Induces Robust and Persistent Humoral and Cellular Immunity. PLoS One 2012, 7(7):e42163.
32. Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors. Immunol. Rev. 2004, 199:227-250.
33. Rathinam V.A., Vanaja S.K., Fitzgerald K.A. Regulation of inflammasome signaling. Nat Immunol 2012, 13(4). (333-2).
34. Ruprecht C.R., A Lanzavecchia Toll-like receptor stimulation as a third signal required for activation of human naive B cells (see comment). Eur. J. Immunol 2006, 36:810-816.
35. Tewari K., Flynn B.J., Boscardin S.B., Kastenmueller K., Salazar A.M., Anderson C.A., Soundarapandian V., Ahumada A., Keler T., Hoffman S.L., Nussenzweig M.C., Steinman R.M., Seder R.A. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 2010, 28(45):7256-7266.
36. Tighe H., Takabayashi K., Schwartz D., Marsden R., Beck L., Corbeil J., Richman D.D., Eiden J.J., Spiegelberg H.L., Raz E. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur. J. Immunol. 2000, 30(7):1939-1947.
37. Wack A., Baudner B.C., Hilbert A.K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., O'Hagan D.T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26(4):552-561.
38. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Nat. Acad. Sci. U.S.A. 1997, 94(20):10833-10837.
39. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Kedl R.M., Mattapallil J.J., Weiss W.R., Roederer M., Seder R.A. HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc. Nat. Acad. Sci. U.S.A. 2005, 102(42):15190-15194.
40. Wille-Reece U., Flynn B.J., Lore K., Koup R.A., Miles A.P., Saul A., Kedl R.M., Mattapallil J.J., Weiss W.R., Roederer M., Seder R.A. Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 2006, 203(5):1249-1258.
41. Wille-Reece U., Wu C.Y., Flynn B.J., Kedl R.M., Seder R.A. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J. Immunol. 2005, 174(12):7676-7683.